Table 1

p53 status and PZA efficacy in neuroblastoma cells lines

Cell linesp53 functionPZA (μm)AUC90cm·h)
LC90aLC99b
Drug-sensitiveSK-N-BE(1)+d0.53.738.9
SMS-SAN+<0.010.10.7
CHLA-15+0.20.614.4
SMS-KAN+0.94.464.8
SMS-KCN+1.15.979.2
SMS-LHN+0.10.59.4
SMS-KANR+0.62.841.0
SMS-KCNR+0.21.012.2
CHLA-20+0.41.626.6
CHLA-42+0.71.346.8
CHLA-8+0.61.543.9
CHLA-51+0.41.829.5
Meane0.411.7529.19
95% CIe(0.24–0.62)(1.05–2.64)(16.75–45.06)
MDR, p53-functionalCHLA-140+0.92.862.6
LA-N-6+0.82.555.4
CHLA-79+2.417.4169.2
CHLA136+1.25.083.5
Mean1.263.3587.89
95% CI(0.73–1.93)(1.46–6.01)(50.50–135.58)
MDR, p53-nonfunctionalSK-N-BE(2)f1.04.769.1
CHLA-1191.12.577.8
CHLA-1710.92.662.6
CHLA-901.53.9108.7
CHLA-134g1.34.391.4
CHLA-1722.13.0151.2
Mean1.293.4591.29
95% CI(0.84–1.83)(2.01–5.27)(59.33–130.12)
  • a LC90, PZA concentration lethal for 90% of treated cells.

  • b LC99, PZA concentration lethal for 99% of treated cells.

  • c AUC90 calculated as LC90 × 72 h.

  • d +, p53 function intact was determined as low basal level of p53 and induction of p21 and/or MDM2 in response to 16-h exposure to 6 μg/ml melphalan by Western blotting.

  • e Means and associated CIs were based on the square root transformed data. LC99 value of CHLA-79 was excluded from analysis as an outlier.

  • f −, loss of p53 function determined as high basal level p53 and failure to induce both p21 and MDM2 in response to 16-h exposure of 6 μg/ml melphalan by Western blotting.

  • g Cell line with loss of p53 function associated with MDM2 genomic amplification.